Biofrontera Inc. (BFRI) News
Filter BFRI News Items
BFRI News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
BFRI News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest BFRI News From Around the Web
Below are the latest news stories about BIOFRONTERA INC that investors may wish to consider to help them evaluate BFRI as an investment opportunity.
Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)Last patient completed 1 year follow-up of study ALA-BCC-CT013 in December 2024.Data from follow-up will be included in FDA submission, expected in Q3 2025.Biofrontera announced highly statistically significant results for all primary and secondary endpoints (p <0.0001) in October 2024.BCC, of which sBCC is a subgroup, is the most common skin cancer in the US with more than 3 million cases each year1. WOBURN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” |
Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US MarketBiofrontera started commercial distribution of the RhodoLED XL in June 2024 and has seen rapid uptake in the US market since launch.The RhodoLED XL is approved by the FDA in combination with Ameluz® (aminolevulinic acid hydrochloride) topical gel, 10% for photodynamic therapy (PDT) of actinic keratoses of mild-to-moderate severity on the face and scalp.Biofrontera’s RhodoLED XL and BF-RhodoLED lamps deliver red light energy using long-lasting light-emitting diode (LED) arrays. WOBURN, Mass., Dec |
Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor ConferenceWOBURN, MA / ACCESSWIRE / December 3, 2024 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced it will ... |
Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible NoteWOBURN, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced the completion of a private placement of a $4.2 million senior secured convertible note (the “Note”) with its principal shareholders. The Note matures on November 22, 2027, bears a paid in kind interest of 10% per annum and is secured by the Company’s asse |
Biofrontera Inc (BFRI) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst Revenue ...Biofrontera Inc (BFRI) reports significant clinical progress and cost reductions, despite weather-related shipment delays impacting Q3 revenue. |
Biofrontera Inc. (BFRI) Reports Q3 Loss, Lags Revenue EstimatesBiofrontera Inc. (BFRI) delivered earnings and revenue surprises of -17.81% and 18.15%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update●Total revenues for the third quarter 2024 were $9.0 million, an increase of 1.5% from Q3 2023. Revenue increase would have been 19% if shipments were not delayed due to Hurricane Milton. ●Total revenues for the first 9 months were $24.8 million, an increase of $1.3 million, or 5.6% as compared to the same period last year. Without the impact of Hurricane Milton delaying shipments, the increase would have been 12%. ●Ameluz® achieved record volume in September 2024. ●Organization continues to pru |
Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024WOBURN, MA / ACCESSWIRE / November 1, 2024 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of PDT, announces it will report financial results for ... |
Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)First Phase 3 PDT study in patients with sBCC in the United States.Primary and secondary endpoints all highly statistically significant p<0.0001Correlates to data seen in Europe where sBCC is already incorporated in the Summary of Product Characteristics.BCC is the most common skin cancer in the US, with more than 3 million cases each year1. WOBURN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing |
Rosalind Advisors, Inc. Reduces Stake in Biofrontera IncRosalind Advisors, Inc. (Trades, Portfolio), a notable investment firm, recently adjusted its investment in Biofrontera Inc (NASDAQ:BFRI), a biopharmaceutical company based in the USA. On September 30, 2024, the firm executed a reduction in its holdings by 8,771 shares, resulting in a new total of 495,490 shares. |